The primary end point was the mean percentage change , from baseline to the end of ASP@ administration , in serum level of alanine aminotransferase ( ALT ) ; secondary outcomes included changes in aspartate aminotransferase ( AST ) levels , ratio of AST : ALT , and various biomarkers of NASH .